Drug profile · INN
anileridine phosphate
LERITINE
anileridine phosphate (LERITINE) is a kappa opioid receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — anileridine phosphate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
anileridine phosphate (LERITINE) is a kappa opioid receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Kappa opioid receptor agonist
Primary target: Kappa-type opioid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is anileridine phosphate?
anileridine phosphate (LERITINE) is a kappa opioid receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for anileridine phosphate?
LERITINE is a marketed brand name for anileridine phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of anileridine phosphate?
anileridine phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.